INTRODUCTION
This review concerns the post-market safety experience of a range of hyaluronic acid (HA) fillers developed by Q-Med AB (Uppsala, Sweden), using Optimal Balance Technology (OBT) TM , known as XpresHAn Technology TM in the US ( Table 1) . 1 Almost 1 million units were sold (ex-US) during the first 5 years on the market; this volume and duration of use allows for a thorough and accurate evaluation of the safety of these products to be conducted. 2 
SUBJECTS and METHODS
Data Collection: • The safety dataset was compiled from post-market surveillance (PMS) reports of adverse events (AEs) received since the products were launched in 2011, including any cases reported in the literature • A total of 302 PMS case reports were included in the analysis • Available safety data obtained from sponsored clinical studies were also collected and reviewed Data Analysis:
• Reporting frequencies for PMS reports were calculated based on the number of units of product sold and on the assumption that 1 unit was used per treatment • AEs classified as related to treatment or as unassessable were considered to be potentially related AEs and were included in the analysis -Potentially related adverse events with similar or associated preferred terms were grouped.
RESULTS
• PMS case reports: Of the total number of AEs (from 302 case reports), 771 were classified as potentially related.
-Overall reporting frequency: 0.033% for the period of 2011 to 2015, within a range between 0.026 to 0.035% per year -Five most common events were: swelling (0.016%), mass/induration (0.011%), pain and tenderness (0.007%), erythema (0.006%), and papules/nodules (0.006%) -The rare reports of delayed onset events of nodules, swelling or inflammation responded to corticosteroids or hyaluronidase -Ten cases were reported as serious (ie, ischemia with or without necrosis, infection, swelling and nodules) • PMS case reports, continued -Time to onset provided for 483 (63%) of the events · 68% of AEs had a time to onset within 28 days after treatment, 77% within 60 days, and 90% within 120 days -Duration was available for 10% of events · Among these events, 85% resolved within 28 days and 95% within 60 days -Information on the event outcome showed that 64% were resolved or resolving, but no information was available for 25% of these events • Reporting frequencies of nodules, inflammatory reactions and granulomas for OBT HA (Table 2) • Safety data from 7 sponsored interventional clinical studies and 1 observational study were reviewed -Studies; 638 subjects followed for 24 weeks to 18 months · No related serious adverse events adverse events reported · AEs on 3 or more occasions in the entire study population: erythema, hematoma, swelling, pain, papules and telangiectasia · Other events reported with lower occurrences were edema, induration, inflammation, pruritus, dermatitis, and skin tightness • The Emervel French survey, a prospective real-practice descriptive study of 1,822 patients treated with multiple products over 15 months 3 -No SAEs reported -Immediate post-treatment assessment showed good local tolerability SUMMARY ■ There is now a 5-year safety experience to give confidence for use of the OBT range (known as XpresHAn Technology TM in the US) of HA fillers ■ There are no new unexpected AEs compared to other established fillers on the market ■ Late onset-AEs that are difficult to treat are very rare ■ The insight gained from real-world practice is that the use of hyaluronidase with or without corticosteroids can treat rare events such as granulomas, delayed onset nodules, and swelling 
